nogrady veracode 2009 - illumina, inc....• micro rna discovery & profiling •wg cspeq-hi •...

38
© 2009 Illumina, Inc. Illumina, Making Sense Out of Life, Sentrix, GoldenGate, DASL, Oligator, Infinium, GenomeStudio, BeadArray, Array of Arrays, BeadXpress, VeraCode, IntelliHyb, iSelect, CSPro, and Solexa are registered trademarks or trademarks of Illumina Inc. VeraCode Technology From Research to Diagnostics June 22, 2009

Upload: others

Post on 01-Oct-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

© 2009 Illumina, Inc.Illumina, Making Sense Out of Life, Sentrix, GoldenGate, DASL, Oligator, Infinium, GenomeStudio, BeadArray, Array of Arrays, BeadXpress, VeraCode, IntelliHyb, iSelect, CSPro, and Solexa are registered trademarks or trademarks of Illumina Inc.

VeraCode TechnologyFrom Research to DiagnosticsJune 22, 2009

Page 2: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

2

Integrated Platform Solutions

110102103104105106107108>109

Discovery Focused Research & Validation Molecular Dx

Whole Genome Single Marker

Genome Analyzer

• WG Resequencing• WG Gene Expression• Micro RNA Discovery &

Profiling• WG ChIP-Seq

• Candidate-Region resequencing

• Whole Chromosome sequencing

• Gene Expression• WG Genotyping• WG CNV• Biomarker Discovery• Cytogenetics

• HT Biomarker/lead validation

• Custom genotyping• Focused expression• DASL for FFPE

• Low/mid density GT/GEX/Methylation

• Protein applications• Biomarker screening• Biomarker panels

iScanTM

BeadXpress

Page 3: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

3

Illumina’s Solution for Diverse Applications

Cylindrical glass microbeads

240 μm length x 28 μm diameter

VeraCode® Technology

Page 4: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

4

VeraCode Technology

CODE IMAGE

1 0 1 1 0 1 0 1 0 0 0 0 1 0 1

BINARY CODE DECIMAL CODE= 41133

CODE GENERATED BY CREATING EMBEDDED HOLOGRAPHIC DIFFRACTIVE ELEMENTS

High Density Codes Easily Imprinted (24 bit)

Virtually Unlimited Unique Bead Codes Available –626 unique codes used in launched products

Glass Surface of Beads Ideal for Bioassays –numerous surface chemistries available

Specific panels created easily with addition or removal of specific bead types

CONVENTIONALCCD CAMERA

BEAD

“READING”BEAM

Page 5: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

5

BeadXpress™ Reader

INSTRUMENT SPECIFICATIONS

Regulatory Design ControlREGULATORY

Optional 1 or 2 color detectionDETECTION

120 samples/hr at 10-plex (two-color detection)80 samples/hr at 96-plex (two-color detection)THROUGHPUT

1 to 384MULTIPLEXING PER SINGLE WELL

Standard 96-well plate & Stripwell PlatesSAMPLE DELIVERY FORMAT

ASSAY BEAD KIT

SAMPLE PLATE

ASSAYCODE

LIBRARY

DATA & LOG FILES

Page 6: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

6

VeraCode Technology

EIGHT WELLS ARE SAMPLED SIMULTANEOUSLY AND MICROBEADS ARE TRANSFERRED INTO A MULTI-SECTORED READER CELL.

Page 7: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

7

VeraCode Technology

GROOVE PLATECROSS-SECTION

BEADS FALLINTO GROOVE

PLATE

CAPILLARY FORCE ATTRACTS BEADS INTO GROOVES

BEADS ALIGN TIGHTLY FOR OPTIMAL SCANNING EFFICIENCY

Page 8: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

8

40

6080

100

120140

160

180200

220

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

90

140

190

240

290

340

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

90

140

190

240

290

340

390

440

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

60

80

100

120

140

160

180

200

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

90

140

190

240

290

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

60

80

100

120

140

160

180

200

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

90

140

190

240

290

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

90

140

190

240

290

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

60

80

100

120

140

160

180

200

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

406080

100120140160180200220240

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

60

80

100

120

140

160

180

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

60

80

100

120

140

160

180

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

60

80

100

120

140

160

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

90

140

190

240

290

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

90

140

190

240

290

340

390

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

60

80

100

120

140

160

180

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

90

140

190

240

290

340

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

40

60

80

100

120

140

160

180

0 20 40 60 80 100

120

140

160

180

200

220

240

Pixel

AD

C O

utpu

t

Code DetectionBEAD

“READING”BEAM

CCD LINE ARRAY

Page 9: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

9

VeraCode Custom Products

Page 10: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

10

Comprehensive VeraCode product portfolio

VeraCode Carboxyl Bead Sets

VeraCode Universal Capture Bead Sets

Custom GoldenGate Genotyping, 48 to 384-plex

DASL Custom Gene Expression, 96 & 384-plex

Custom GoldenGate Methylation, 96 & 384-plex

Page 11: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

11

Available Products

CARBOXYL BEAD SETS (PROTEIN BASED ASSAYS)

Unique Bead Code Types in

Tubes

Assay DesignGuidelines

(RUO)

CUSTOMER DEVELOPED ASSAY

+

GUIDELINESPRODUCT

Customer controls level of multiplexing and number of samples

Page 12: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

12

COOH-

COOH-

COOH-

COOH-

COOH-

COOH-

COOH-

COOH-

COOH-

COOH-

COOH-

COOH-

COOH-

COOH-

Activate Surface Covalently BindEDC/Sulfo-NHSAntibodiesAntigensPeptides

Streptavidin

NUCLEIC ACID ATTACHMENT: ONE-STEP PROCESS

EDC/Sulfo-NHS plus NH2+Oligo NucleicAcids

PROTEIN ATTACHMENT: TWO-STEP PROCESS

Carboxyl Beads: Chemistry of Attachment

Page 13: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

13

Cytokine Sandwich Assay Overview

PEPE

PE

CytokineAntigens

BiotinylatedSecondary Antibody

PE

StreptavidinPhycoerythrin

PEPEPE

Antibodies immobilizedvia COOH surface and EDClinker chemistry

VeraCode Bead

Page 14: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

14

Available Products

UNIVERSAL CAPTURE BEAD SETS

Unique Bead Code Types in

Tubes

Assay DesignGuidelines

(RUO)

CUSTOMER DEVELOPED ASSAYS

+

GUIDELINESPRODUCT

Customer controls level of multiplexing and number of samplesVeraCode Primer

Design Software

Page 15: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

15

Allele-Specific Primer Extension (ASPE)

Biotin-NTP’sIncorporated

Wild-Type

C B

B

Variant

AGG

C

AGG

C

Primer Not ExtendedPrimer Extended

MismatchMatch

A

Page 16: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

16

The VeraCode Assay Designer Solution

Access user-specific accounts

Input SNP targets

Choose workflow option

Customize design parameters

Select among possible assay designs

Download detailed ordering information

Page 17: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

17

SAP/EXO

Prepare Microtitre

PlateMultiplex

ASPEMultiplex

PCR

Multiplex ASPE Genotyping Protocol

Add ASPESample Hybridize Detection

Scan

User definedKitting Options

Total Hands On Time ~ 1.5 hr/plateTotal Time (Sample to Answer) ~ 6.5 hours

Total Hands On Time ~ 1.5 hr/plateTotal Time (Sample to Answer) ~ 6.5 hours

Page 18: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

18

Low Plex ASPE Genotyping Results

0 10000 20000 30000 40000

Intensity (A)

FII

0

10000

20000

Inte

nsi

ty (

B)

0 2000 4000 6000 8000 1000012000 1400016000 180002000022000 2400026000

Intensity (A)

FV

-2000

0

2000

4000

6000

8000

10000

12000

14000

16000In

ten

sity

(B

)

0 10000 20000 30000

Intensity (A)

MTHFR667

0

10000

Inte

nsi

ty (

B)

0 2000 4000 6000 8000 100001200014000160001800020000220002400026000

Intensity (A)

MTHFR1298

-2000

0

2000

4000

6000

8000

10000

12000

14000

16000

Inte

nsi

ty (

B)

≥ 99.99% reproducibility

100% concordant genotypes

Page 19: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

19

Customer Success

Sciona – Health and Wellness company offering genetic testing and personalized exercise, diet and lifestyle recommendations

– Validated assays presented in October 28, 2008 Webinar1

– GSTM1: Deletion of GSTM1 associated with compromised detoxification– GSTT1: Deletion of GSTT1 associated with compromised detoxification– ALDH2: 487 G->A associated with alcohol intolerance– CYP1A1: 462 A->G associated with increased metabolism of carcinogens

Children's Hospital of Eastern Ontario – Newborn screening laboratory testing 135,000 children per year

– Assay development presented at 2008 Illumina Seminar Series2

– HbC, HbE, HbSickle, HbO and HbF: Hemaglobinopathy panel – SMA – Spinal Muscular Atrophy assay looks at gene copy number variation

associated with severity of muscular disease

1: http://www.illumina.com/webinars/archives/archivesWebinars.ilmn?entry=50&w=20

2: http://www.illumina.com/seminars/archive/Crocker_0808_NewbornScreening.pdf

Page 20: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

20

Available Products

GOLDENGATE GENOTYPING ASSAY (48, 144, 192 & 384-PLEX)

Assay specific oligos

+Reagents

GoldenGate Genotyping User Manual

(RUO)

GOLDENGATEGENOTYPING

+Beads Pooled in

96-well Plates

(48 to 384-plex/well)

USER MANUALCustom GoldenGate

Page 21: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

21

AG

AddressAllele Specific Extension &Ligation

Universal PCR Sequence 1

Universal PCR Sequence 2

Universal PCR Sequence 3’

GoldenGate Genotyping AssayAllele Specific Extension and Ligation

Genomic DNA [T/C] Ligase [T/A]Polymerase

Page 22: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

22

A Address #561Amplification Template

PCR with Common Primers

GoldenGate Genotyping AssayAmplification

Cy3 Universal Primer 1

Cy5 Universal Primer 2

Universal Primer P3

Page 23: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

23

Hybridization to VeraCode Beads – one SNP per bead type

GoldenGate Assay – two color detection

/\/\/\

/

/\/\/\

/

/\/\/\

/

illumiCode #561

illumiCode #217

illumiCode #1024

/\/\/\

/

/\/\/\

/

A/A G/G C/T

SNP #561 SNP #217 SNP #1024

Bead Code 6457

Bead Code 6002

Bead Code 5433

Page 24: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

24

GoldenGate Assay Results

41,184

Total # of Data Points

100%100%99.9%28696

HeritabilityReproducibilityCall RateSamples Tested

Reaction Multiplex

0 0.20 0.40 0.60 0.80 1

Norm Theta

rs2020911

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

48 134 104

0 0.20 0.40 0.60 0.80 1

Norm Theta

rs3136329

0

0.20

0.40

0.60

0.80

1

No

rm R

111 131 420 0.20 0.40 0.60 0.80 1

Norm Theta

rs6748810

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

1.80N

orm

R

97 145 420 0.20 0.40 0.60 0.80 1

Norm Theta

rs1800937

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

1.80

No

rm R

2 42 2410 0.20 0.40 0.60 0.80 1

Norm Theta

rs1005056

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

No

rm R

252 33 00 0.20 0.40 0.60 0.80 1

Norm Theta

rs2059520

0

0.20

0.40

0.60

0.80

1

No

rm R

97 137 450 0.20 0.40 0.60 0.80 1

Norm Theta

rs4148217

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

No

rm R

10 96 1770 0.20 0.40 0.60 0.80 1

Norm Theta

rs13320360

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

No

rm R

268 13 00 0.20 0.40 0.60 0.80 1

Norm Theta

rs1498311

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

28 106 1520 0.20 0.40 0.60 0.80 1

Norm Theta

rs13282019

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

No

rm R

0 44 2390 0.20 0.40 0.60 0.80 1

Norm Theta

rs673548

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

No

rm R

12 77 1960 0.20 0.40 0.60 0.80 1

Norm Theta

rs4784744

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

44 152 900 0.20 0.40 0.60 0.80 1

Norm Theta

rs3825585

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

No

rm R

0 38 246

0 0.20 0.40 0.60 0.80 1

Norm Theta

rs4289236

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

19 82 1840 0.20 0.40 0.60 0.80 1

Norm Theta

rs10514805

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

No

rm R

0 33 2510 0.20 0.40 0.60 0.80 1

Norm Theta

rs4953020

0

0.20

0.40

0.60

0.80N

orm

R

27 105 1530 0.20 0.40 0.60 0.80 1

Norm Theta

rs6720173

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

8 84 1940 0.20 0.40 0.60 0.80 1

Norm Theta

rs3136245

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

No

rm R

29 75 1820 0.20 0.40 0.60 0.80 1

Norm Theta

rs1799898

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

No

rm R

13 61 2120 0.20 0.40 0.60 0.80 1

Norm Theta

rs820299

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

98 147 41

0 0.20 0.40 0.60 0.80 1

Norm Theta

rs3258

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

No

rm R

135 101 500 0.20 0.40 0.60 0.80 1

Norm Theta

rs5927

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

1.80

2.00

No

rm R

16 95 1730 0.20 0.40 0.60 0.80 1

Norm Theta

rs8110695

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

11 70 2030 0.20 0.40 0.60 0.80 1

Norm Theta

rs9326954

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

No

rm R

94 140 520 0.20 0.40 0.60 0.80 1

Norm Theta

rs3791981

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

No

rm R

224 59 00 0.20 0.40 0.60 0.80 1

Norm Theta

rs4952887

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

No

rm R

11 44 2290 0.20 0.40 0.60 0.80 1

Norm Theta

rs1042031

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

1.80

2.00

No

rm R

8 103 1750 0.20 0.40 0.60 0.80 1

Norm Theta

rs2072447

0

0.20

0.40

0.60

0.80

1

No

rm R

173 89 24

0 0.20 0.40 0.60 0.80 1

Norm Theta

rs2569538

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

No

rm R

1 31 2540 0.20 0.40 0.60 0.80 1

Norm Theta

rs4647247

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

No

rm R

0 13 2700 0.20 0.40 0.60 0.80 1

Norm Theta

rs10515198

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

0 40 2400 0.20 0.40 0.60 0.80 1

Norm Theta

rs1801702

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

No

rm R

3 11 2710 0.20 0.40 0.60 0.80 1

Norm Theta

rs4647229

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

No

rm R

276 6 00 0.20 0.40 0.60 0.80 1

Norm Theta

rs1800947

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

23848 00 0.20 0.40 0.60 0.80 1

Norm Theta

rs265431

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

No

rm R

225 59 1

0 0.20 0.40 0.60 0.80 1

Norm Theta

rs2645424

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

No

rm R

51 136 940 0.20 0.40 0.60 0.80 1

Norm Theta

rs9353019

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

1.80

2.00

No

rm R

1 21 2640 0.20 0.40 0.60 0.80 1

Norm Theta

rs2303152

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

0 33 2500 0.20 0.40 0.60 0.80 1

Norm Theta

rs5882

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

117 119 500 0.20 0.40 0.60 0.80 1

Norm Theta

rs1616534

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

83 153 470 0.20 0.40 0.60 0.80 1

Norm Theta

rs1736058

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

1.80

No

rm R

4 96 1800 0.20 0.40 0.60 0.80 1

Norm Theta

rs1800932

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

196 81 90 0.20 0.40 0.60 0.80 1

Norm Theta

rs3805586

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

30 139 1170 0.20 0.40 0.60 0.80 1

Norm Theta

rs13425206

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

No

rm R

0 19 2650 0.20 0.40 0.60 0.80 1

Norm Theta

rs4987188

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

4 12 2700 0.20 0.40 0.60 0.80 1

Norm Theta

rs289741

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

128 112 45

0 0.20 0.40 0.60 0.80 1

Norm Theta

rs9326953

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

168 111 70 0.20 0.40 0.60 0.80 1

Norm Theta

rs748766

0

0.20

0.40

0.60

0.80

1

No

rm R

91 114 800 0.20 0.40 0.60 0.80 1

Norm Theta

rs12056593

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

No

rm R

280 6 00 0.20 0.40 0.60 0.80 1

Norm Theta

rs1146634

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

78 157 510 0.20 0.40 0.60 0.80 1

Norm Theta

rs5930

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

1.80

2.00

No

rm R

63 127 930 0.20 0.40 0.60 0.80 1

Norm Theta

rs4647221

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

No

rm R

253 31 00 0.20 0.40 0.60 0.80 1

Norm Theta

rs4236927

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

263 23 00 0.20 0.40 0.60 0.80 1

Norm Theta

rs7607312

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

No

rm R

70 159 560 0.20 0.40 0.60 0.80 1

Norm Theta

rs267307

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

No

rm R

21963 20 0.20 0.40 0.60 0.80 1

Norm Theta

rs916042

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

1.80

No

rm R

19 35 2300 0.20 0.40 0.60 0.80 1

Norm Theta

rs6741393

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

1.80

No

rm R

0 23 263

0 0.20 0.40 0.60 0.80 1

Norm Theta

rs6718187

0

1

2

No

rm R

64 138 84

0 0.20 0.40 0.60 0.80 1

Norm Theta

rs5880

0

0.20

0.40

0.60

0.80

1

No

rm R

3 24 259

0 0.20 0.40 0.60 0.80 1

Norm Theta

rs533617

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

1.60

1.80

No

rm R

261 24 0

0 0.20 0.40 0.60 0.80 1

Norm Theta

rs17320429

-0.20

0

0.20

0.40

0.60

0.80

1

1.20

1.40

No

rm R

257 19 10

Page 25: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

25

Inter-User Variability

9696OPA multiplex

100%

100%99.97%

100%100%99.96%

144

95

User A

100%

98.94%99.74%

100%100%99.92%

User B

99.97%> 99.0%Call Rate100%> 95%Sample Success Rate

100%> 99.5%Heritability (Parent/Parent/Child)

Results

100%> 90%Locus Success Rate

100%100%

User C

> 99.0%Reproducibility> 99.5%Concordance

144Bead Multiplex

95Number of DNA Samples

Setup

TargetSpecification

Page 26: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

26

The DASL Assay

/WV/WV

Product capture by hybridization to array

PCR with common primers

Address’P1

P1

P3’

P3

Address

b

b

Total RNA

cDNA synthesis

Query oligo annealing, extension, and ligation

P2

P2

cDNA synthesis includes random priming for fragmented RNAs.

Sequences of ~ 50 nt are targeted for analysis by addressed query oligos.

PCR primers are shared among all targets, and amplicons are a uniform size.

Reproducible across a wide range of RNA degradation.

Page 27: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

27

GoldenGate Methylation Assay

1. Bisulfite treatment of DNA● Convert unmethylated cytosine to uracil

2. GoldenGate Assay• DNA Activation

• Allele-Specific Extension (ASE) & Ligation

• PCR Amplification

• Hybridize to Bead Substrate

• Scan

Page 28: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

28

GoldenGate Methylation AssayHybridization & Detection

IllumiCode

IllumiCode

IllumiCode

CpG locus 1 CpG locus 2

CpG locus 3

Unmethylated

U/U

Methylated

C/C

Semi-methylated

C/U

Page 29: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

29

BeadXpress – Application Versatility

100000

10000

1000

100

10

10.1 1 10 100 1000 10000

Conc (pM)

Cou

nts

AnalyteFit3-sigma LOD

GENE REGULATION PROTEIN EXPRESSION

GENOTYPING

0 1 2 3 4 5

Log10(Conc pg/ml)

IL-6 (6152)

2

3

4

5

Lo

g1

0(N

et R

FU

)

Page 30: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

30

The road to diagnostics

Page 31: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

31

Bridging from the lab to the clinic

BeadXpress

• Collaborative approach to research

• Constantly improving throughput

• Excellent cost position

• Highly multiplexed

• Multiple markers on one system

Laboratory Translate Clinic

Genome Analyzer

iScan

Services

Page 32: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

32

Applications in pharmacogenetics

Whole Genome Association study using Illumina’s HumanHap550

Replication analysis with VeraCode GoldenGate 384-plex on loci associated with Warfarin dose at P value ≤ 10-4 in the index patient population

Conclusions: Common SNPs with large effects on warfarin dose are unlikely to be discovered outside of the CYP2C9 and VKORC1 genes. Randomized clinical trials that account for these 2 genes should therefore produce results that are definitive and broadly applicable.

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance doseCooper GM, Johnson JA, Langaee TY et al. (2008) Blood 112: 1022-1027

BeadXpressiScan

From Whole Genome Association To

Focused analysis and Validation

VeraCode 384plex GGGTHuman Hap550 (>550K SNPS)

Page 33: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

33

To Be the Leader in Cancer Translational Diagnostics

Illumina Diagnostics Vision

Next Generation Sequencing

Whole Transcriptome Analysis

Methylation Profiling

Focus Core Technologies on Cancer

Page 34: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

34

Ovarian Cancer Will be Our Entry Point

Deadly

Leading cause of death from gynecological cancerFifth leading cause of cancer mortality in womenMortality: 15,520 (US Only)

Laparotomy/Hysterectomy/Remove ovariesFollowed with six cycles of chemotherapyLess than 40% are cured

Incurable

Abdominal/pelvic exam, Ultrasound, CT, CA-125Patients present with a suspicious/palpable massBRCA 1/2 positive in a limited number of cases

Difficult Dx

Page 35: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

35

Early Detection for Ovarian Cancer is Critical

Cumulative % of Cases

19% 22%

30% 33%37% 40%

47%

54%

72%

100%

Ia Ib Ic Iia Iib Iic IIa IIIb IIIc IV

Stage at Diagnosis

Late stage diagnosis …

5 Year Survival92%

85%82%

69%

56%51%

39%

26%

17%12%

Ia Ib Ic Iia Iib Iic IIa IIIb IIIc IV

Stage

… results in poor prognosis

Page 36: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

36

Gastric Cancer will be Our Second Target

Cardia 15% of Gastric CancersIncreasing due to obesity

Normal

Superficial Gastritis

Atrophic Gastritis

Small intestine Metaplasia

Colonic Metaplasia

Dysplasia

Carcinoma

High pH

Bacterial Growth

N=O Mutagens

NO3-Ascorbic Acid

NaClBeta Carotene

Gastric Carcinogenesis

Page 37: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

37

Discovery, Strategy & AdvantagesFocused Approach Addresses Unmet Medical Needs

Begin with 25 Tumor/Normal pairs

Comprehensive genetic analysis

Sequence to 30x coverage whole genome

Analyze full methylome and transcriptome

Validate findings on larger sample size

Implement on flexible platform

Blood TypingStrategy Illumina Advantage

Low cost internal sequencing

Significant throughput improvements

- Currently 1 genome/week internally

Unique bioinformatics capability - Multiple genome analysis

Capable of analyzing across methods

Ability to deploy content on arrays

BeadXpress optimal for multiplemethods

Page 38: NOGrady VeraCode 2009 - Illumina, Inc....• Micro RNA Discovery & Profiling •WG CSPeq-hI • Candidate-Region resequencing •We Cholomhroomse sequencing • Gene Expression •

38

Oncology Discovery – Identify novel biomarkers

Sequencing Services – Utilize service lab for rapid translation

Platform Partnering – Build a large installed base

Illumina Diagnostics StrategyTo be the leader in cancer translational diagnostics

• Identify novel biomarkers for the early detection of ovarian cancer• Identify novel biomarkers to indicate response to platinum therapy in late stage ovarian cancer

• Establish a CLIA laboratory• Begin to offer services in the oncology area based on the ovarian biomarkers

• Partner with content providers• Enable broad adoption with removal of royalty burden• Internally develop products to create breadth of menu